Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
European Journal of Clinical Investigation ; 52(11), 2022.
Article in English | CAB Abstracts | ID: covidwho-2278001

ABSTRACT

The objective of this work is to expand the information provided in the ATAC study, showing the viral load measurements by means of RT-qPCR in tracheobronchial samples from a group of patients with moderate COVID-19, before and after 5 days of standard treatment with aprotinin compared with standard treatment with placebo. The samples of the current study were rescued from participants of a multicentre, double-blind, parallel-arm, randomized phase III trial, performed in four Spanish hospitals with the same inclusion criteria at baseline. Viral load was compared between placebo group and aprotinin-treated group at two time points. At the pre-time (i.e. day 0 before treatment), no significant differences were observed between groups. However, at post-time (i.e. treatment day 5), viral load levels were significantly lower in the aprotinin-treated group. Additionally, a comparative analysis was performed between the placebo group and the aprotinin group. A significantly shorter treatment time was observed in the aprotinin-treated group (p = 0.032), as well as a greater decrease in viral load (p = 0.016). The remaining variables showed no differences between both groups.

2.
Revista Ecuatoriana de Neurologia ; 31(1):108-112, 2022.
Article in Spanish | EMBASE | ID: covidwho-1897370

ABSTRACT

The respiratory system is mainly affected by the SARS-CoV-2 infection, producing a severe acute respiratory syndrome known as COVID-19 (Coronavirus disease 2019), patients with severe disease usually develop multiorgan failure;among these we can focus on the nervous system, due to its potential neurotropism. Recent clinical data reveal that patients may manifest symptoms such as anosmia, dysgeusia, impaired consciousness, headache, seizures, and cerebrovascular disease (CVD). We describe two physically active male patients with complicated SARS-CoV-2 infection without significant comorbidities related to the development of intracranial hemorrhage, nor a history of head trauma or documented anatomic malformations. Both were admitted by the emergency department and during their stay in the ICU they developed intracranial hemorrhage diagnosed by computed tomography. The paraclinical findings in the two cases were compatible with a prothrombotic state as possible etiologies of bleeding in both.

SELECTION OF CITATIONS
SEARCH DETAIL